FDAnews
www.fdanews.com/articles/72745-ablynx-and-the-national-research-council-canada-sign-deal

Ablynx and the National Research Council Canada Sign Deal

May 27, 2005

Ablynx, a pioneer in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments, announced that it has signed a collaborative research, development and license agreement with the Ottawa-based National Research Council of Canada (NRC) Institute for Biological Sciences (IBS).This collaboration will make an important contribution to Ablynx's discovery efforts in the area of neurodegenerative diseases.

()a href="http://www.pharmalive.com/News/index.cfm?articleid=243415&categoryid=15" target="_blank">PharmaLive